Murray Stahl's BIIB Position Overview
Murray Stahl (via Horizon Kinetics Asset Management LLC) currently holds 2,988 shares of Biogen Inc. (BIIB) worth $525,858, representing 0.01% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Murray Stahl has maintained a long-term strategic position in BIIB, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2024, adding 129 shares. Largest reduction occurred in Q1 2017, reducing 2,010 shares.
Analysis based on 13F filings available since 2013 Q2
Murray Stahl's Biogen (BIIB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Biogen (BIIB) Trades by Murray Stahl
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -131 | Reduce 4.20% | 2,988 | $175.99 |
| Q3 2025 | +81 | Add 2.67% | 3,119 | $140.08 |
| Q2 2025 | -131 | Reduce 4.13% | 3,038 | $125.59 |
| Q4 2024 | +129 | Add 4.24% | 3,169 | $152.92 |
| Q3 2024 | -81 | Reduce 2.60% | 3,040 | $193.84 |
| Q1 2024 | +2 | Add 0.06% | 3,121 | $215.63 |
| Q4 2023 | -131 | Reduce 4.03% | 3,119 | $258.77 |
| Q1 2023 | -500 | Reduce 13.33% | 3,250 | $278.03 |
| Q4 2021 | -125 | Reduce 3.23% | 3,750 | $240.00 |
| Q2 2021 | -50 | Reduce 1.27% | 3,875 | $346.32 |
| Q1 2021 | -29 | Reduce 0.73% | 3,925 | $279.75 |
| Q4 2020 | -45 | Reduce 1.13% | 3,954 | $244.82 |
| Q2 2020 | -125 | Reduce 3.03% | 3,999 | $267.57 |
| Q1 2020 | -130 | Reduce 3.06% | 4,124 | $316.44 |
| Q4 2019 | -275 | Reduce 6.07% | 4,254 | $296.66 |
| Q3 2019 | -100 | Reduce 2.16% | 4,529 | $232.72 |
| Q2 2019 | +125 | Add 2.78% | 4,629 | $233.96 |
| Q1 2019 | +54 | Add 1.21% | 4,504 | $236.46 |
| Q4 2018 | -75 | Reduce 1.66% | 4,450 | $300.90 |
| Q3 2018 | -50 | Reduce 1.09% | 4,525 | $353.37 |
| Q1 2018 | -70 | Reduce 1.51% | 4,575 | $273.88 |
| Q1 2017 | -2,010 | Reduce 30.20% | 4,645 | $273.41 |
| Q4 2016 | -1,050 | Reduce 13.63% | 6,655 | $283.70 |
| Q4 2015 | -8 | Reduce 0.10% | 7,705 | $306.42 |
| Q3 2015 | -620 | Reduce 7.44% | 7,713 | $291.84 |
| Q2 2015 | -115 | Reduce 1.36% | 8,333 | $403.94 |
| Q1 2015 | -69 | Reduce 0.81% | 8,448 | $422.23 |
| Q4 2014 | +49 | Add 0.58% | 8,517 | $339.44 |
| Q3 2014 | -25 | Reduce 0.29% | 8,468 | $330.77 |
| Q1 2014 | -39 | Reduce 0.46% | 8,493 | $305.90 |
| Q4 2013 | -51 | Reduce 0.59% | 8,532 | $279.54 |
| Q3 2013 | -43 | Reduce 0.50% | 8,583 | $240.82 |
| Q2 2013 | +8,627 | Add 0.00% | 8,626 | $215.16 |
Murray Stahl's Biogen Investment FAQs
Murray Stahl first purchased Biogen Inc. (BIIB) in Q2 2013, acquiring 8,626 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl has held Biogen Inc. (BIIB) for 51 quarters since Q2 2013.
Murray Stahl's largest addition to Biogen Inc. (BIIB) was in Q2 2013, adding 8,626 shares worth $1.86 M.
According to the latest 13F filing for Q4 2025, Murray Stahl's firm, Horizon Kinetics Asset Management LLC, owns 2,988 shares of Biogen Inc. (BIIB), valued at approximately $525,858.
As of the Q4 2025 filing, Biogen Inc. (BIIB) represents approximately 0.01% of Murray Stahl's publicly disclosed stock portfolio, making it one of their key holdings.
Murray Stahl's peak holding in Biogen Inc. (BIIB) was 8,626 shares, as reported at the end of Q2 2013.